Get the latest news, insights, and market updates on VRCA (Verrica Pharmaceuticals Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. H.C. Wainwright 27th Annual Global Investment Conference, Sep Sep 2, 2025 - $VRCA
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
– Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii Pharmaceutical – – Completed Successful End of Phase 2 Meeting for VP-315 for Basal Cell Carcinoma; Company is preparing for the Phase 3 program and exploring non-dilutive opportunities for financing further development – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTE Aug 12, 2025 - $VRCA
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update. Individuals may participate in Aug 6, 2025 - $VRCA
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts – WEST CHESTER, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications Jul 9, 2025 - $VRCA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.